VBL Therapeutics (NASDAQ:VBLT) is having an incredibly strong time in the pre-market hours this morning, and for good reason. The company got great news from the Independent Data Safety Monitoring Committee surrounding one of its trials. As a result, investors got excited, pushing the stock upward. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:07), VBLT is trading at $5.55 per share after a gain of 6.73% thus far today.
VBLT Announces Positive DSMC Review
As mentioned above, VBL Therapeutics is having a strong time in the market this morning after announcing positive news with regard to an ongoing Phase 3 clinical trial. The company announced that the Independent Data Safety Monitoring Committee has met to conduct its second safety review of the company’s Phase 3 GLOBE Study. In the study, VB-111 is being investigated as a treatment for rGBM. The members of the DSMC unanimously recommended that the study continue as planned after evaluating potential safety concerns. In a statement, Dror Harats, CEO at VBLT had the following to offer…
“We are pleased with the outcome of the DSMC… Based on enrollment trends and events that triggered the DSMC review, we currently expect the GLOBE Trial interim analysis to occur in mid-2017, and top-line results from the full dataset to be available in early 2018.”
Stop wasting your time! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on VBLT. In particular, we’ll be watching for any news associated with VB-111 as the treatment continues to look promising mid-study. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!
Want The News Faster?
Check out the CNA Finance News Desk to get the scoop before we have time to write the full story!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Wikimedia]